Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Retained Earnings data on record, last reported at $163000.0 in Q3 2025.

  • For Q3 2025, Retained Earnings fell 76.06% year-over-year to $163000.0; the TTM value through Sep 2025 reached $163000.0, down 76.06%, while the annual FY2024 figure was $106000.0, 125.53% up from the prior year.
  • Retained Earnings reached $163000.0 in Q3 2025 per DNTH's latest filing, up from $98000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $681000.0 in Q3 2024 and bottomed at -$365.8 million in Q2 2022.
  • Average Retained Earnings over 4 years is -$70.8 million, with a median of -$4000.0 recorded in 2023.
  • The widest YoY moves for Retained Earnings: up 17125.0% in 2024, down 4025833.33% in 2024.
  • A 4-year view of Retained Earnings shows it stood at -$45.9 million in 2022, then soared by 100.1% to $47000.0 in 2023, then surged by 125.53% to $106000.0 in 2024, then skyrocketed by 53.77% to $163000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $163000.0 in Q3 2025, $98000.0 in Q2 2025, and $270000.0 in Q1 2025.